Laurel Wealth Advisors Inc. boosted its stake in shares of Eli Lilly and Co (NYSE:LLY) by 16.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,789 shares of the company’s stock after purchasing an additional 833 shares during the period. Laurel Wealth Advisors Inc.’s holdings in Eli Lilly and were worth $488,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Gradient Investments LLC purchased a new position in Eli Lilly and during the fourth quarter valued at $103,000. Avestar Capital LLC purchased a new position in shares of Eli Lilly and in the 4th quarter worth $100,000. MPS Loria Financial Planners LLC purchased a new position in shares of Eli Lilly and in the 2nd quarter worth $128,000. San Francisco Sentry Investment Group CA purchased a new position in shares of Eli Lilly and in the 2nd quarter worth $129,000. Finally, Willingdon Wealth Management purchased a new position in shares of Eli Lilly and in the 3rd quarter worth $138,000. Institutional investors and hedge funds own 77.63% of the company’s stock.
NYSE LLY traded down $1.77 on Friday, hitting $76.85. 4,012,649 shares of the company’s stock traded hands, compared to its average volume of 4,066,183. The company has a current ratio of 1.32, a quick ratio of 1.01 and a debt-to-equity ratio of 0.85. Eli Lilly and Co has a 1-year low of $73.69 and a 1-year high of $89.09. The stock has a market cap of $86,135.91, a price-to-earnings ratio of 17.96, a PEG ratio of 1.43 and a beta of 0.26.
Eli Lilly and (NYSE:LLY) last posted its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.06. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 33.01%. The firm had revenue of $6.16 billion during the quarter, compared to analysts’ expectations of $5.93 billion. During the same period in the previous year, the business posted $0.95 EPS. The business’s revenue was up 7.0% compared to the same quarter last year. analysts forecast that Eli Lilly and Co will post 4.87 EPS for the current year.
In other Eli Lilly and news, SVP Jeffrey N. Simmons sold 9,625 shares of the company’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $81.12, for a total transaction of $780,780.00. Following the completion of the transaction, the senior vice president now directly owns 152,120 shares in the company, valued at $12,339,974.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Donald A. Zakrowski sold 876 shares of the company’s stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $77.55, for a total transaction of $67,933.80. Following the completion of the sale, the insider now directly owns 4,130 shares of the company’s stock, valued at approximately $320,281.50. The disclosure for this sale can be found here. Over the last quarter, insiders sold 15,261 shares of company stock valued at $1,225,085. Company insiders own 0.11% of the company’s stock.
Several equities research analysts have recently issued reports on the stock. BMO Capital Markets restated a “sell” rating and issued a $74.00 target price on shares of Eli Lilly and in a report on Wednesday. Credit Suisse Group reiterated a “hold” rating and set a $80.00 price objective on shares of Eli Lilly and in a report on Friday, February 2nd. TheStreet lowered shares of Eli Lilly and from a “b” rating to a “c” rating in a report on Monday, March 5th. Argus upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and boosted their price target for the company from $85.52 to $115.00 in a report on Friday, January 5th. Finally, Zacks Investment Research lowered shares of Eli Lilly and from a “buy” rating to a “hold” rating in a report on Tuesday, March 27th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $92.84.
TRADEMARK VIOLATION NOTICE: “Laurel Wealth Advisors Inc. Raises Stake in Eli Lilly and Co (LLY)” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/07/laurel-wealth-advisors-inc-increases-stake-in-eli-lilly-and-co-lly.html.
About Eli Lilly and
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.